A Conjugated Linoleic Acid Supplement Containing Trans-10, Cis-12 Conjugated Linoleic Acid Reduces Milk Fat Synthesis in Lactating Goats¹

Temporal pattern of (A) milk yield, (B) milk protein percentage, and (C) milk lactose percentage of lactating goats un-supplemented (control; ■) or supplemented with lipid-encapsulated conjugated linoleic acid (CLA) at a low dose (CLA-1; △) and a high dose (CLA-2; ×). Values represent means from 30 does; SEM = 85 g/d, 0.04%, and 0.04% for milk yield, milk protein percentage, and milk lactose percentage, respectively.

Temporal pattern of (A) milk fat percentage and (B) milk fat yield of lactating goats unsupplemented (control; □) or supplemented with lipid-encapsulated conjugated linoleic acid (CLA) at a low dose (CLA-1; △) and a high dose (CLA-2; ×). Values represent means from 30 does; SEM = 0.06% and 5.0 g/d for milk fat percentage and milk fat yield, respectively.

Milk fatty acid yield (mmol/d) in goats (n = 30) that were unsupplemented (control; black bars) or supplemented with lipid-encapsulated conjugated linoleic acid (CLA) at a low (CLA-1; open bars) and a high dose (CLA-2; cross-hatched bars). Values for individual fatty acids were calculated using milk fat yield treatment means for d 11 to 14 and milk fatty acid composition from d 14 of treatment. Fatty acids are categorized according to origin; <C16 represent de novo synthesized fatty acids, >C16 represent preformed fatty acids taken up from circulation, and C16 fatty acids are derived from both sources. Standard error is indicated by error bars over each column. ^a-cWithin each fatty acid source, treatment effects with significance differences are indicated by letters over the columns (P<0.001 for all).